Core Insights - Bright Green Corporation (OTC: BGXX) has merged with PharmAGRI Capital Partners to enhance U.S. drug manufacturing sovereignty through a court-supervised restructuring plan [1] - Lynn Stockwell has been appointed as the CEO and Chairwoman of PharmAGRI, with plans to form a new board from her acquisition corps focused on DEA-licensed and FDA-compliant pharmaceutical businesses [2] - PharmAGRI's model emphasizes a "seed to syringe" approach for drug manufacturing entirely in the U.S., supporting EB-5 investor pathways and federal contracts [3] Company Strategy - PharmAGRI has signed a Letter of Intent with Tesla to deploy up to 10,000 Optimus 3+ humanoid robots for various operations, aimed at improving labor compliance and reducing reliance on low-wage labor [4] - The strategic vision includes on-shoring pharmaceutical production, enhancing wages, and establishing a sovereign infrastructure to secure federal contracts and strengthen the U.S. supply chain [5] - PharmAGRI plans to file a Form S-1 registration statement with the SEC and aims for a Nasdaq relisting, with a proposed reverse stock split and preferred share issuance pending approval [5][6] Market Positioning - The company intends to complete its IPO by the end of 2025, which will facilitate market access and strategic expansion within the U.S. pharmaceutical infrastructure [6]